| BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Lucie EHRLICHOVÁ, Květoslava MATULOVÁ, Eliška GAZÁRKOVÁ, Luboš MINÁŘ and Vít WEINBERGER. Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents? Cancers. Basel: MDPI, 2022, vol. 14, No 10, p. 1-13. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers14102353. |
Other formats:
BibTeX
LaTeX
RIS
@article{1858546,
author = {Bednaříková, Markéta and Hausnerová, Jitka and Ehrlichová, Lucie and Matulová, Květoslava and Gazárková, Eliška and Minář, Luboš and Weinberger, Vít},
article_location = {Basel},
article_number = {10},
doi = {http://dx.doi.org/10.3390/cancers14102353},
keywords = {SLFN11; ovarian cancer; high-grade serous carcinoma; DNA-damaging agents; PARPi; chemoresistance},
language = {eng},
issn = {2072-6694},
journal = {Cancers},
title = {Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?},
url = {https://www.mdpi.com/2072-6694/14/10/2353},
volume = {14},
year = {2022}
}
TY - JOUR
ID - 1858546
AU - Bednaříková, Markéta - Hausnerová, Jitka - Ehrlichová, Lucie - Matulová, Květoslava - Gazárková, Eliška - Minář, Luboš - Weinberger, Vít
PY - 2022
TI - Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?
JF - Cancers
VL - 14
IS - 10
SP - 1-13
EP - 1-13
PB - MDPI
SN - 20726694
KW - SLFN11
KW - ovarian cancer
KW - high-grade serous carcinoma
KW - DNA-damaging agents
KW - PARPi
KW - chemoresistance
UR - https://www.mdpi.com/2072-6694/14/10/2353
N2 - Platinum-based chemotherapy has been the cornerstone of systemic treatment in ovarian cancer. Since no validated molecular predictive markers have been identified yet, the response to platinum-based chemotherapy has been evaluated clinically, based on platinum-free interval. The new promising marker Schlafen 11 seems to correlate with sensitivity or resistance to DNA-damaging agents, including platinum compounds or PARP inhibitors in various types of cancer. We provide background information about the function of Schlafen 11, its evaluation in tumor tissue, and its prevalence in ovarian cancer. We discuss the current evidence of the correlation of Schlafen 11 expression in ovarian cancer with treatment outcomes and the potential use of Schlafen 11 as the key predictive and prognostic marker that could help to better stratify ovarian cancer patients treated with platinum-based chemotherapy or PARP inhibitors. We also provide perspectives on future directions in the research on this promising marker.
ER -
BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Lucie EHRLICHOVÁ, Květoslava MATULOVÁ, Eliška GAZÁRKOVÁ, Luboš MINÁŘ and Vít WEINBERGER. Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents? \textit{Cancers}. Basel: MDPI, 2022, vol.~14, No~10, p.~1-13. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers14102353.
|
